SAINT for Treatment of Preoperative Depression to Reduce Opioid Use Following Arthroplasty

Sponsor

Stanford University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT04195308

Collaborator

(none)

Enrollment

Location

Arms

Anticipated Duration (Months)

1.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In a double-blind fashion, half the participants will receive accelerated theta-burst stimulation while half will receive sham treatment.

Condition or Disease	Intervention/Treatment	Phase
Treatment Resistant Depression	Device: Active TBS-DLPFC Device: Sham TBS-DLPFC Device: Open label TBS-DLPFC	N/A

Detailed Description

Repetitive transcranial magnetic stimulation (rTMS) is an established technology as therapy for treatment-resistant depression. The approved method for treatment is 10Hz stimulation for 40 min over the left dorsolateral prefrontal cortex (L-DLPFC). This methodology has been effective in real world situations. The limitations of this approach include the duration of the treatment (approximately 40 minutes per treatment session, 5 days per week, for 4-8 weeks). Recently, researchers have pursued modifying the treatment parameters to reduce treatment times with some preliminary successes. This study aims to further modify the parameters to create a more rapid form of the treatment and look at the change in neuroimaging biomarkers.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

60 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Care Provider, Investigator)

Primary Purpose:

Treatment

Official Title:

Accelerated Intermittent Theta-burst Stimulation for Treatment of Preoperative Depression to Reduce Conversion of Acute to Chronic Opioid Use Following Arthroplasty

Anticipated Study Start Date :

Jun 1, 2022

Anticipated Primary Completion Date :

Nov 1, 2024

Anticipated Study Completion Date :

Nov 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Active TBS-DLPFC The active group will receive theta-burst TMS stimulation.	Device: Active TBS-DLPFC Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004). Stimulation will be delivered to the L-DLPFC using a MagPro stimulator.
Sham Comparator: Sham TBS-DLPFC The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.	Device: Sham TBS-DLPFC The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion. Device: Open label TBS-DLPFC Patients will have the option of receiving active, open label aTBS treatment following sham. Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device.

Arm

Intervention/Treatment

Experimental: Active TBS-DLPFC

The active group will receive theta-burst TMS stimulation.

Device: Active TBS-DLPFC

Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004). Stimulation will be delivered to the L-DLPFC using a MagPro stimulator.

Sham Comparator: Sham TBS-DLPFC

The sham group will receive sham theta-burst TMS stimulation. Participants will have the option of open label TBS-DLPFC treatment following study completion.

Device: Sham TBS-DLPFC

The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.

Device: Open label TBS-DLPFC

Patients will have the option of receiving active, open label aTBS treatment following sham. Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device.

Outcome Measures

Primary Outcome Measures

Change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from pre-treatment to 1-month post-treatment. [Pretreatment to 1-month posttreatment]
A ten item diagnostic questionnaire used to measure the severity of depressive episodes in patients with mood disorders.

Secondary Outcome Measures

Percentage change in the Hamilton Rating Scale for Depression (HAMD-17) [4 weeks posttreatment]
A provider administered questionnaire used to assess remission and recovery from depression.
Percentage change in the Columbia Suicide Severity Rating Scale (C-SSRS) [Pretreatment, immediately posttreatment, 2 weeks posttreatment, 4 weeks posttreatment]
A suicidal ideation rating scale created by researchers at Columbia University.
Percentage change in the Hamilton Rating Scale for Depression (HAM-6) [Follow-up every 2 weeks for 6 months by telephone]
A 6 item questionnaire used to score the severity of depression.
Percentage change in the Hamilton Rating Scale for Depression (HAMD-17) [Pretreatment, immediately posttreatment, 2 weeks posttreatment]
A provider administered questionnaire used to assess remission and recovery from depression.
Change in baseline functional connectivity to immediate post-treatment using functional MRI [Pretreatment to immediately posttreatment]
MR imaging of the brain to measure the functional connectivity between the subcallosal cingulate to the default mode network.
Change in baseline functional connectivity to 1-month post-treatment [Pretreatment to 1-month post-treatment]
The investigators will assess functional connectivity as seen on resting state fMRI, between the subcallosal cingulate to the default mode network and within the default mode network.
Change in baseline heart rate variability through immediate post treatment and 1-month post treatment [Pretreatment, immediately posttreatment and 1-month post treatment]
Heart rate variability measures will be compared baseline, immediate post treatment and 1-month post treatment

Eligibility Criteria

Criteria

Ages Eligible for Study:

22 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female, 22 to 80 years of age.
Able to provide informed consent.
Diagnosed with Major Depressive Disorder (MDD) and currently experiencing a Major Depressive Episode (MDE).
Participants may currently be on a stable and adequate dose of SSRI antidepressant therapy. Participants may choose to not be on antidepressant therapy for the study duration, or to be switched from other classes to a medication from the SSRI class.
Participants may also have a history of intolerance to at least 2 antidepressant medications. These patients with the intolerance history will not be required to be currently taking an antidepressant medication.
Participants must qualify as "Moderately Treatment Refractory" or "High Treatment Refractory" using the Maudsley staging method.
Meet the threshold on the total HAMD17 score of >/=20 at both screening and baseline visits (Day -5/-14 and Day 0).
Meet the threshold on the total MADRS score of >/=20 at both screening and baseline visits (Day -5/-14 and Day 0).
Meet the threshold on the total BDI-II score of >/=20 at both screening and baseline visits (Day -5/-14 and Day 0).
In good general health, as ascertained by medical history.
If female, a status of non-childbearing potential or use of an acceptable form of birth control. The form of birth control will be documented at screening and baseline.
Concurrent hypnotic therapy (e.g., with zolpidem, zaleplon, melatonin, or trazodone) will be allowed if the therapy has been stable for at least 4 weeks prior to screening and if it is expected to remain stable.

Exclusion Criteria:

Female of childbearing potential who is not willing to use one of the specified forms of birth control during the study.
Female that is pregnant or breastfeeding.
Female with a positive pregnancy test at participation.
Total HAMD17 score of < 20 at the screen or baseline visits.
Total MADRS score of < 20 at the screen or baseline visits.
Total BDI-II score of < 20 at the screen or baseline visits.
Current diagnosis of a Substance Use Disorder (Abuse or Dependence, as defined by DSM-IV-TR), with the exception of nicotine dependence, at screening or within six months prior to screening.
Current diagnosis of Axis I disorders other than Dysthymic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder, Agoraphobia, or Specific Phobia (unless one of these is comorbid and clinically unstable, and/or the focus of the participant's treatment for the past six months or more).
History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes.
Any Axis I or Axis II Disorder, which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within six months prior to screening.
Considered at significant risk for suicide during the course of the study.
Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results.
Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation.
Any current or past history of any physical condition which in the investigator's opinion might put the subject at risk or interfere with study results interpretation.
History of positive screening urine test for drugs of abuse at screening: cocaine, amphetamines, barbiturates, opiates.
Current (or chronic) use of opiates.
History of epilepsy.
History of rTMS exposure.
History of any implanted device or psychosurgery for depression.
History of ECT intolerance.
History of shrapnel or metal in the head or skull.
"Low Treatment Refractory" using the Maudsley staging method.
History of cardiovascular disease or cardiac event.
History of OCD.
History of autism spectrum disorder.
History of intractable migraine
History of independent sleep disorder.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine	Stanford	California	United States	94305

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator: Nolan Williams, MD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:

Nolan R, Assistant Professor, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford University

ClinicalTrials.gov Identifier:

NCT04195308

Other Study ID Numbers:

IRB-53022

First Posted:

Dec 11, 2019

Last Update Posted:

May 10, 2022

Last Verified:

May 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Yes

Product Manufactured in and Exported from the U.S.:

Keywords provided by Nolan R, Assistant Professor, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford University

transcranial magnetic stimulation

theta burst

Additional relevant MeSH terms:

Depression

Depressive Disorder

Depressive Disorder, Treatment-Resistant

Study Results

No Results Posted as of May 10, 2022